Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA3 | P07451 | 1/20 | 0.45 |
| ▸ | CA4 | P22748 | 1/20 | 0.45 |
| ▸ | CA6 | P23280 | 1/20 | 0.45 |
| ▸ | CA5A | P35218 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.45 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.30 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.30 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.30 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18271825 | 1.00 | LMNA (0.45) | LMNACA12CA1CA2CA3 | |
| SCHEMBL28798027 | 0.88 | LMNA (0.33) | LMNACA12CA1CA2CA3 | |
| SCHEMBL2360484 | 0.80 | LMNA (0.49) | LMNACA12CA1CA2CA3 | |
| SCHEMBL3054095 | 0.80 | LMNA (0.49) | LMNACA12CA1CA2CA3 | |
| SCHEMBL2331554 | 0.72 | LMNA (0.46) | LMNACA12CA1CA2CA3 | |
| SCHEMBL3060780 | 0.72 | LMNA (0.46) | LMNACA12CA1CA2CA3 | |
| SCHEMBL10239591 | 0.69 | LMNA (0.39) | LMNACA12CA1CA2CA3 | |
| SCHEMBL21881949 | 0.69 | LMNA (0.35) | LMNACA12CA1CA2CA3 | |
| SCHEMBL3046245 | 0.68 | LMNA (0.50) | LMNACA12CA1CA2CA3 | |
| SCHEMBL2333742 | 0.68 | LMNA (0.50) | LMNACA12CA1CA2CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116041240-B | Asymmetric catalytic hydrogenation synthesis method of brivaracetam intermediate | 扬州奥锐特药业有限公司 | 2024-04-09 | — | — | CN | disclosed |
| US-20230277501-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY | 2023-09-07 | — | — | US | disclosed |
| US-11673862-B2 | Processes to produce brivaracetam | SUZHOU PENGXU PHARMATECH CO. LTD. (CN) | 2023-06-13 | — | — | US | disclosed |
| CN-116041240-A | Asymmetric catalytic hydrogenation synthesis method of brivaracetam intermediate | 扬州奥锐特药业有限公司 | 2023-05-02 | — | — | CN | disclosed |
| US-20230033195-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY | 2023-02-02 | — | — | US | disclosed |
| US-11518741-B2 | Brivaracetam intermediate, preparation method therefor, and preparation method for brivaracetam | SHANGHAI PUYI CHEMICAL CO., LTD. (CN) | 2022-12-06 | — | — | US | disclosed |
| US-20220265685-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY | 2022-08-25 | — | — | US | disclosed |
| US-11160785-B2 | Methods and compositions for improving cognitive function | AGENEBIO INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-20210253523-A1 | BRIVARACETAM INTERMEDIATE, PREPARATION METHOD THEREFOR, AND PREPARATION METHOD FOR BRIVARACETAM | SHANGHAI PUYI CHEMICAL CO., LTD. (CN) | 2021-08-19 | — | — | US | disclosed |
| EP-3371150-B1 | PROCESS FOR PREPARING BRIVARACETAM | UCB Biopharma SRL (BE) | 2021-08-18 | — | — | EP | disclosed |
| EP-2152262-A2 | NEW HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | UCB Pharma, S.A. (BE) | 2010-02-17 | — | — | EP | disclosed |
| EP-1452524-B1 | \"2-oxo-1-pyrrolidine derivative and its pharmaceutical uses\ | UCB PHARMA SA (BE) | 2009-10-14 | — | — | EP | disclosed |
| WO-2008132139-A2 | NEW HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | UCB PHARMA S.A. (BE) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008132142-A2 | NEW HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | UCB PHARMA S.A. (BE) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008132142-A2 | NEW HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | UCB PHARMA S.A. (BE) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008132139-A2 | NEW HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | UCB PHARMA S.A. (BE) | 2008-11-06 | — | — | WO | disclosed |
| US-20080097109-A1 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UCB BIOPHARMA SPRL (BE) | 2008-04-24 | — | — | US | disclosed |
| US-20080097109-A1 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UCB BIOPHARMA SPRL (BE) | 2008-04-24 | — | — | US | disclosed |
| US-7358276-B2 | for treating neurological disorders such as epilepsy, neuropathic pain, bipolar disorder or migraine; 2-(2-oxo-4-propyl-1-pyrrolidinyl)butanamide; neuroprotective agent | UCB, S.A. (BE) | 2008-04-15 | — | — | US | disclosed |
| US-7358276-B2 | for treating neurological disorders such as epilepsy, neuropathic pain, bipolar disorder or migraine; 2-(2-oxo-4-propyl-1-pyrrolidinyl)butanamide; neuroprotective agent | UCB, S.A. (BE) | 2008-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11673862-B2 | Processes to produce brivaracetam | BLVRB, CYP3A4, POR | LMNA 3886/4885CA12 2526/4885CA1 4013/4885 |
| US-20080097109-A1 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | CYP1B1, OGDH, CYP1A2 | LMNA 3694/4885CA12 4426/4885CA1 2098/4885 |
| US-11160785-B2 | Methods and compositions for improving cognitive function | BACE2, BACE1, GRIN2A | LMNA 1020/4885CA12 483/4885CA1 828/4885 |
| US-11518741-B2 | Brivaracetam intermediate, preparation method therefor, and preparation method for brivaracetam | CYP51A1, FAR1, POR | LMNA 2989/4885CA12 2880/4885CA1 3969/4885 |
| US-20210253523-A1 | BRIVARACETAM INTERMEDIATE, PREPARATION METHOD THEREFOR, AND PREPARATION METHOD FOR BRIVARACETAM | CYP51A1, FAR1, POR | LMNA 2989/4885CA12 2880/4885CA1 3969/4885 |
| US-20230277501-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | GRIN2A, CHRNA2, SYNGR2 | LMNA 1805/4885CA12 302/4885CA1 322/4885 |
| US-20220265685-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | BACE1, BACE2, ACHE | LMNA 763/4885CA12 825/4885CA1 350/4885 |
| US-20230033195-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | GRIN2D, GRIN2A, SLC18A2 | LMNA 1152/4885CA12 123/4885CA1 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.